Answers are grounded in this paper and cite their sources.
Acquired resistance to osimertinib remains a major challenge in EGFR‐mutant non‐small cell lung cancer (NSCLC). Using an osimertinib‐resistant (AR) cell model lacking the on‐target EGFR C797S mutation, we uncover sustained AKT phosphorylation under osimertinib treatment driven by insulin receptor (INSR) signaling. Notably, INSR–AKT activation is observed exclusively in AR cells, whereas parental H1975 cells fail to activate AKT even following INSR overexpression or exogenous insulin stimulation. Cholesterol depletion abolishes the INSR–AKT response in AR cells, indicating a lipid raft‐dependent mechanism. Consistently, INSR localizes within lipid rafts in AR but not in parental H1975 cells. Proteomic profiling reveals the enrichment of lipid raft‐associated proteins in AR cells. Among them, flotillin‐1 (FLOT1) is identified as a key raft scaffold mediating INSR–AKT signaling and osimertinib resistance through functional shRNA screening. Co‐immunoprecipitation and proximity ligation assay confirm a cholesterol‐dependent interaction between FLOT1 and INSR. Functionally, FLOT1 knockdown disrupts raft‐associated INSR localization, attenuates AKT activation, and reduces the IC 50 of osimertinib in AR cells. Collectively, these findings demonstrate that lipid raft‐dependent INSR–AKT signaling contributes to osimertinib resistance in NSCLC.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: